Initially, there was a concern regarding an increased risk of bladder cancer with the use of SGLT2 inhibitors due to constant exposure of the urinary tract to glycosuria, deterring their potential novel applications [30]. This evidence concerns the gene SLC5A2 and urinary bladder carcinoma.